The placenta plays a key role in pregnancy, mediating exchanges between mother and fetus and maternal tolerance of fetopaternal antigens. In some species, it also produces hormones that ensure the maintenance of gestation and fetal well-being. This unique organ also has considerable potential for use as a model for various aspects of biology. Indeed, the use of transgenic mouse models has greatly improved our understanding of the genetic control of placental development in this species and has opened up new ®elds of investigation in developmental biology. Analogous cell types have been identi®ed among human and murine trophoblasts: proliferative trophoblastic cells, invasive trophoblastic cells and cells differentiating into syncytium, but human and mouse placentas differ in both morphogenesis and endocrine function. Herein, the similarities and differences between the human and mouse models are reviewed, with a view to encouraging caution in the extrapolation of results from one model to the other.
Introduction
The placenta is a unique, autonomous and transient organ which is responsible for maternal-fetal exchanges and maternal tolerance of fetopaternal antigens. In some species, the placenta performs hormonal functions required for the maintenance of gestation and fetal well-being. The placenta has also been used as a model for various aspects of biology, including cell biology, development, endocrinology, immunology and angiogenesis.
The transgenic mouse model, with its possibilities for gene knock-out and gene targeting, has vastly improved our understanding of the genetic control of placental development in the mouse, and has opened up new ®elds of investigation in developmental biology. These studies have identi®ed analogous cell types among human and murine trophoblasts, including proliferative trophoblastic cells, invasive trophoblastic cells and cells differentiating into syncytium (Rossant and Cross, 2001; Cross et al., 2002) .
Human placenta differs from mouse placenta in its morphogenesis and endocrine functions however, and consequently investigators must bear in mind the limitations of the models they are using. This review raises a number of issues concerning the extrapolation to humans of the results of experimental studies conducted in rodents.
Mouse and human placental development
Mice and humans differ in the time and trigger of uterine decidualization during gestation. Decidualization involves the transformation of uterine stromal cells into large decidual cells with a secretory phenotype, and the recruitment of specialized populations of bone marrow-derived cells (macrophages, granulated lymphocytes, etc.). In the mouse, embryo implantation induces decidualization (Enders and Welsh, 1993) , whereas in humans the ®rst signs of decidualization are seen before conception, as early as day 23 of the normal menstrual cycle, when the spiral arteries of the endometrium become prominent (Kliman, 2000) . Decidualization indicates that the uterine cavity as a whole is ready for embryo implantation. Interestingly, extrauterine pregnancies are not uncommon in humans (Kemp et al., 2002; Gof®n et al., 2003) , whereas they are unknown in mice (Bischof and Campana, 1999) , thus illustrating a speci®c difference between these two species in terms of implantation.
In humans, the de®nitive structure of the placenta becomes apparent as early as day 21 of pregnancy Benirschke and Kaufmann, 2000) . Following blastocyst adhesion, extremely rapid trophoblast proliferation begins and trophoblast cells undergo cell fusion to form the multinucleated syncytiotrophoblast, which invades the maternal uterine stroma. By day 21 after ovulation, the chorionic villusÐthe de®nitive functional and structural unit of the placentaÐis already established. The trophoblast differentiates in two waysÐthe villous and the extravillous trophoblast. In the villous phenotype, the cytotrophoblastic cells of the¯oating villi (in the intervillous space) remain attached to the villous basement membrane, forming a monolayer of epithelial cells. These cells proliferate and differentiate, by fusion, to form a syncytiotrophoblast that covers the entire surface of the villus (Figure 1, panel B) . This membrane fusion process involves the so-called`phosphatidylserine¯ip' (Adler et al., 1995) , and the synthesis of an endogenous retroviral envelope protein (Blond et al., 2000; Mi et al., 2000; Frendo et al., 2003a) , connexin 43 (Cronier et al., 2003; Frendo et al., 2003b) and cadherin 11 (Getsios and MacCalman, 2003) . The syncytiotrophoblast is multifunctional, but its primary functions are absorption, exchanges and speci®c hormonal functions. In the extravillous phenotype, the cytotrophoblast cells of the anchoring villi in contact with the uterine wall proliferate, detach from the basement membrane, and aggregate into multilayered columns of non-polarized cells that rapidly invade the uterus wall. This trophoblastic invasion is con®ned to the endometrium, the ®rst third of the myometrium, and the associated spiral arterioles. Thus, the trophoblast invades the maternal tissue via two different routes. The ®rst occurs via the uterine stroma (interstitial invasion) and involves the migration of trophoblastic cells towards the decidual arterial wall or the differentiation of cells scattered throughout the decidua and myometrium into multinucleated placental giant cells (Figure 1 , panel E). These giant cells increase in number throughout gestation and appear to arise from the fusion of extravillous trophoblasts (al-Lamki et al., 1999; Lyall, 2002) . In the second invasion route, the extravillous trophoblastic cells in®ltrate the lumens and walls of the arteries, resulting in endovascular invasion. This invasion process is associated with complete remodelling of the spiral artery wall, resulting in disappearance of the muscle layer and the replacement of endothelial cells by trophoblasts (Pijnenborg et al., 1981; Lim et al., 1997; Kaufmann et al., 2003) (Figure 1, panel D) . Some studies have suggested that the initial dilatation and transformation of the spiral arteries occur independently of direct trophoblast invasion (Craven et al., 1998) . Currently, relatively little is known about endovascular invasion, and the studies carried out have generated con¯icting results (Kaufmann et al., 2003) . However, trophoblastic endovascular invasion is of major importance in fetoplacental physiology: intra-arterial plugs, consisting of endovascular trophoblasts, prevent maternal blood from entering the intervillous space until the 12th week of gestation, thereby protecting the conceptus from excessively high oxygen levels during this very critical stage of development (Hustin and Schapps, 1987; Hustin et al., 1990; Burton et al., 1999) . De®cient arterial remodelling is also involved in pre-eclampsia, a disorder that is speci®c to human pregnancy and which manifests during the second trimester of pregnancy, with maternal hypertension and proteinuria.
Unlike the human placenta, the mouse placenta appears not to achieve its de®nitive structure until halfway through gestation (Figure 2 ). Indeed, during the 19±20 days of gestation in mice, placentation evolves from an initially choriovitelline pattern to a chorioallantoic pattern at 11.5 days ( Figure 2 ). As mouse placental development has been elegantly described in other reviews (Rossant and Cross 2001; Downs 2002; Georgiades et al., 2002) , we will provide only a brief summary, as illustrated in Figure 2 . During the ®rst stage of placentation, the trophectoderm differentiates in two pathways: (i) polar trophoblastic cells displaying rapid proliferation, giving rise to the extraembryonic ectoderm and ectoplacental cone; and (ii) mural trophoblastic cells that do not divide but instead continue to endoreplicate their DNA, forming primary trophoblastic giant cells. Meanwhile, the endoderm differentiates within the inner cell mass of the embryo. Parietal endoderm cells migrate onto the basal surface of the trophoblast layer and deposit an extensive basement membrane (Reichert membrane) between the trophoblast giant cells and the parietal endoderm. This ®rst placental structureÐthe parietal yolk sacÐ absorbs nutrients from the maternal blood via capillary channels in the decidual tissue that gradually form sinuses between the primary trophoblastic giant cells and the Reichert membrane. On day 8 of gestation, mesoderm cells from the embryo migrate to the inner surface of the visceral endoderm and give rise to the ®rst vascular cells and primitive vitelline vessels (visceral yolk sac). At this stage, nutrient exchanges are ensured by this vascularized zone. These mesodermal cells also form the allantoid mesenchyme, which develops and enters into contact with the chorion of the ectoplacental cone on days 9±10. In the chorioallantoic placenta, the allantoic mesoderm gradually invades trophoblastic cells and establishes a network of fetal blood vessels in the developing labyrinthine zone. By 12.5 days of gestation, the de®nitive chorioallantoic placenta is clearly subdivided into: (i) a layer of maternal decidua; (ii) a junctional zone (Figure 1 , panel C); and (iii) a labyrinthine zone (Figure 1, panel A) . The maternal decidua comprises mesometrial decidual cells and large granular lymphocytes. The junctional zone is limited on the maternal side by a layer of trophoblastic giant cells. Recently, detailed examination of histological sections of these zones has revealed that trophoblastic giant cells are also present within and around the lumen of the maternal decidual spiral arteries very close to this junctional zone (Adamson et al., 2002) . Mouse giant trophoblastic cells, despite bearing the same name, are not analogous to their human counterparts. Indeed, mouse giant cellsÐlike other rodent giant cellsÐare generated by endoreplication (Soares et al., 1996) , which does not occur in humans.
The mouse junctional zone also includes two types of cytotrophoblast: (i) spongiotrophoblasts with an eosinophilic cytoplasm; and (ii) trophoblastic glycogen cells. The trophoblastic glycogen cells decrease in number in this zone late in gestation, progressively invading the decidua. In mice, trophoblastic glycogen cells do not begin to invade the decidua basalis until day 13, which is relatively late in gestation; the invasion process is not completed until days 15 to 18. Furthermore, trophoblastic invasion in mice does not extend into the myometrium (Enders and Welsh, 1993 ) and endovascular invasion is very limited. The labyrinth develops from the trophoblast and its associated fetal blood vessels. In the labyrinth, the trophoblast begins to differentiate into three layers: two syncytiotrophoblast layers in contact with the fetal endothelium, and one cytotrophoblast layer in contact with maternal blood. Therefore, three trophoblast layers separate the maternal blood from the fetal blood; this type of placental development is known as haemotrichorial placentation (Enders, 1965) . The maternal blood supply crosses the spongiotrophoblast layer via arterial sinuses in which the endothelial cells have been replaced by spongiotrophoblast cells (Adamson et al., 2002) . The maternal blood then enters the labyrinth and bathes the fetal trophoblast, allowing exchanges with fetal blood (Wynn, 1968; Hernandez-Verdun, 1974; Steven and Morris, 1975; Muntener and Hsu, 1977; Georgiades et al., 2002) . Recent analysis of Gcm1 mutants demonstrated that the shaping of the intervillous maternal blood spaces of the labyrinth is directly controlled by placental trophoblast cells (Adamson et al., 2002) .
In mice, the de®nitive structure of the placenta is therefore completed halfway through gestation, and trophoblast invasion occurs late in gestation, in a spatially and temporally discrete manner.
The point in gestation at which fetal nutrition involves direct nutrient uptake from circulating maternal blood by trophoblast cellsÐand the interrelations between maternal and fetal bloodÐ differ in mouse and human placentas (Leiser and Kaufmann, 1994) . The mouse labyrinthine structure allows countercurrent exchanges between maternal and fetal capillaries arranged in parallel to each other. This is considered to be the most effective structure for such exchanges. In humans, the multivillous structure is intermediate between a countercurrent and a parallel-¯ow system and is considered to be less ef®cient (Dantzer et al., 1988; Leiser and Kaufmann, 1994) .
Despite these considerable differences in placental development between mice and humans, some elements of placental development are similar in the two species. For example, the trophoblast cell lineage seems to follow the same pathways: an invasive pathway involving extravillous trophoblasts in humans and giant cells and trophoblastic glycogen cells in mice; and an exchange pathway involving the syncytiotrophoblast in both species. Furthermore, certain transcription factors involved in the expression of various placental genes have been recently described in both human and mouse placenta (Kno È¯er et al., 2001; Rossant and Cross, 2001; Cross et al., 2003) .
Mouse and human placental endocrine functions
Mouse and human placental endocrine functions are very different (Figure 3) . Progesterone, which promotes uterine quiescence, is required throughout gestation. The principal difference between mice and humans is the mechanism controlling transition of the cyclic corpus luteum into a gestational corpus luteum, allowing the maintenance of progesterone secretion (Figure 3 ). In mice, the corpus luteum has to produce progesterone throughout gestation (Strauss et al., 1996) . Corpus luteum function in mice is regulated by prolactin-like or lactogen hormones. Twice-daily surges in prolactin production by the pituitary gland are induced by mating, and this prolactin is the predominant luteotrophic hormone during the ®rst 8±9 days of gestation. Mouse placental lactogen 1 (mPL 1) is produced by trophoblastic giant cells and is detected in the maternal bloodstream. The concentration of this hormone peaks on day 10 then declines after day 11 and remains low. Mouse placental lactogen 2 (mPL 2) levels increase rapidly until day 14 and then remain high until the end of pregnancy. These placental lactogens exert their physiological effects by binding to the same corpus luteum membrane receptor (Galosy and Talamantes, 1995) . Placental lactogen production takes over from pituitary prolactin production, and hypophysectomy after day 11 therefore does not Figure 2 . Comparative developmental evolution of mouse and human placenta. In mouse, placentation changes from an initially choriovitelline pattern to a chorioallantoic pattern at 11.5 days. In the de®nitive chorioallantoic placenta, the labyrinth is made up of trophoblastic septae containing a core of fetal mesenchyme. The trophoblast is differentiated into two syncytial layers in contact with the fetal endothelium and one cellular layer forming the wall of the maternal sinuses. The junctional zone is composed of vacuolated`glycogen cells',`spongiotrophoblastic cells' and secondary`trophoblastic giant cells'. By day 13 of gestation, interstitial invasion of the decidua basalis by the trophoblastic glycogen cells occurs. In humans, the de®nitive chorioallantoic placenta appears by day 21 of pregnancy. At around 10±12 weeks of pregnancy (diagram), the chorionic¯oating villi are bathed by the maternal blood in the intervillous space. In these villi, cytotrophoblastic cells differentiate by fusion to generate the syncytiotrophoblast. In the anchoring villi the cytotrophoblastic cells proliferate and invade the decidua (interstitial invasion). The in®ltrating cells eventually differentiate into multinucleated giant cells. The cytotrophoblastic cells also invade the lumen of maternal arteries (endovascular invasion) remodelling the spiral artery.
result in the termination of pregnancy in mice (Strauss et al., 1996) . The deleterious effect of ovariectomy at any point in gestation con®rms the absolute requirement of the corpus luteum, despite the identi®cation of certain steroidogenic enzymes, such as cytochrome P450 (P450scc) (Schiff et al., 1993) and 3b hydroxysteroid-dehydrogenase type VI (HSD VI) in trophoblastic giant cells, during early pregnancy, as reported in other rodents (Yamamoto et al., 1994) . Interestingly, P450scc and 3b HSD VI were identi®ed upon decidualization of the uterine wall induced by implantation. The second major difference is that genes encoding enzymes involved in steroidogenesis are not expressed in the mature mouse placenta during the second half of gestation, whereas they are expressed in the placenta late in gestation in humans (Ben-Zimra et al., 2002) .
The human pituitary gland is not required for the initiation and maintenance of pregnancy. Maintenance of the corpus luteum during the ®rst 8 weeks of pregnancy depends on hCG produced by the trophectoderm (Jameson and Hollenberg, 1993; Srisuparp et al., 2001; Maston and Ruvolo, 2002) . This glycoprotein hormone is detected in the mother's serum soon after conception (9±10 days after ovulation). The maternal serum hCG concentration then increases exponentially, peaking at 10 weeks and declining thereafter. hCG acts as a LH super-agonist, extending the progestational function of the corpus luteum. After 8 weeks of gestation, placental progesterone production by the syncytiotrophoblast is suf®cient to maintain pregnancy despite ovariectomy. hCG is composed of two subunits, an alpha subunit which is common to all glycoprotein hormones (FSH, LH and TSH), and a beta subunit. The alpha subunit is a 92-amino acid polypeptide with two N-linker oligosaccharides; it is encoded by a single gene on chromosome 6q21.1-23. The speci®c beta subunit is a 145-amino acid polypeptide with two N-linked oligosaccharides and four O-linked oligosaccharides. This subunit is encoded by a cluster of genes consisting of six CG beta genes, one CG beta pseudogene and one LH beta gene, on chromosome 19q13.3. Interestingly, the CG beta genes, which evolved by duplication of an LH beta gene, display differential regulation at the level of the promoter. The 31-amino acid carboxy-terminal extension of hCG and its strong glycosylation targets this protein to the apical membrane of the syncytiotrophoblast, directs its secretion directly into maternal blood, and ensures a long half-life in the maternal bloodstream (Jablonka-Shariff et al., 2002) . In addition to its major role in maintaining the corpus luteum, hCG is involved in autocrine and paracrine mechanisms regulating trophoblast differentiation. hCG enhances the spontaneous differentiation of isolated cytotrophoblasts into syncytiotrophoblasts (Shi et al., 1993; Yang et al., 2003) . This process is preceded by the formation of gap junctions, a process that is also up-regulated by exogenous hCG (Cronier et al., 1994; 2002) . In a recent study, hCG was characterized as a novel angiogenic factor involved in the implantation and normal development of the placenta (Zygmunt et al., 2002) . The human trophoblast expresses two types of hCG receptor: a truncated 50 kDa isoform and an 80 kDa full-length isoform (Licht et al., 1993) . The truncated isoform is expressed during the ®rst trimester of pregnancy, and the full-length isoform is expressed in the highly differentiated term trophoblast. Other hCG receptors have been identi®ed in non-gonad tissue and shown to be involved in the normal course of pregnancy (Licht et al., 2001; Rao, 2001a,b) . To our knowledge, no informative mutations affecting hCG genes have been described, suggesting that hCG is absolutely required for the initiation of pregnancy. The reason for the peak in hCG concentration in the maternal bloodstream early in gestation is unclear, but the following hypotheses have been put forward:
1. Expression at this stage of pregnancy of the truncated hCG receptor isoform may impair the autocrine regulation of hCG biosynthesis (Licht et al., 1993) .
2. The mechanisms regulating hCG gene transcription may differ in early and late placental development, as suggested by the higher levels of hCG production and secretion by early In mouse, progesterone (P4) production by the corpus luteum (CL) is required throughout gestation. During the ®rst 8±9 days of gestation, mouse pituitary prolactin (mPRL) regulates corpus luteum functions; mouse placental lactogen 1 (mPL 1) and mouse placental lactogen 2 (mPL 2) produced by the trophoblastic giant cells take over from pituitary production. Thus, hypophysectomy does not terminate mouse pregnancy when performed after day 11. E2 = estradiol. (B) In humans, the pituitary gland is not required for the initiation and maintenance of pregnancy. Maintenance of the corpus luteum (CL) depends on hCG produced by the trophoblast. After 8 weeks of gestation, placental progesterone (P4) production by the syncytiotrophoblast is suf®cient to maintain pregnancy even in cases of ovariectomy. Human placental hormone function is also characterized by increases in the production of human chorionic somatomammotrophic hormone (hCS) and human placental growth hormone (hPGH).
trophoblasts than by trophoblasts at later stages Frendo et al., 2000) .
3. hCG may be subject to autocrine/paracrine regulation by a GnRH produced by the large population of cytotrophoblastic cells present in early pregnancy (Islami et al., 2001) . Several recent studies have demonstrated the importance of the glycosylation state of hCG, which varies with the stage of pregnancy (DiazCueto et al., 1996) . Choriocarcinoma cells (Eliot et al., 1997) and trophoblast cells displaying chromosome 21 trisomy (Frendo et al., 2003c) produce abnormal glycosylated forms of hCG with low biological activity. It should be noted that no CG beta genes have been found in mice (Maston and Ruvolo, 2002 ). Thus, a major, absolutely required human gestational hormone is not produced during gestation in mice.
Another unique feature of the human placenta is its intense trophoblast steroidogenic activity. Human trophoblasts secrete estrogen and progesterone in much larger amounts than do the trophoblasts of other mammals (Albrecht and Pepe, 1990; Pepe and Albrecht, 1995) . The term human placenta produces about 300 mg of progesterone per day, which is ten times the amount secreted by the mid-luteal-phase corpus luteum (Strauss et al., 1996) . This progesterone is synthesized in the syncytiotrophoblast from maternal lipoprotein cholesterol, and is principally secreted into the maternal compartment (local tocolytic uterine and systemic circulation), but also into the fetal compartment, in which it is converted into fetal adrenal steroids [cortisol and dehydroepiandrosterone (DHEA)]. Progesterone synthesis involves the activity of P450scc and 3b HSD. There are no known cases of human P450scc de®ciency (Reaume et al., 1992) . Unlike other steroidogenic organs, the placenta does not express cytochrome P450 17a-hydroxylase-17:20-lyase(P450c17) and cannot transform progesterone into androgens. Placental estrogen synthesis therefore depends on a source of androgen precursors, DHEA-sulphate (DHEA-SO 4 ), produced by the maternal adrenal gland and by the expanded zone of the fetal adrenal gland. This interdependence has given rise to the concept of the`fetoplacental unit'. Fetal adrenal DHEA-SO 4 can also undergo 16-a-hydroxylation in the fetal liver to produce 16a-DHEA-SO 4 , an androgen precursor of estriol. DHEAS and 16-a-hydroxy-DHEA diffuse from the fetal blood to the syncytiotrophoblast, where they are hydrolysed by a steroid sulphatase to produce androgens. These androgens are then aromatized by syncytiotrophoblastic cytochrome P450 aromatase to generate estrogens, most of which are secreted into the maternal compartment. Studies of two genetic diseases have demonstrated that placental estrogen synthesis (at least at high levels) is not required for the maintenance of human pregnancy. Human pregnancies can reach term, even if the placenta lacks steroid sulphatase despite very low urinary estriol excretion and low unconjugated estrogen levels in the plasma (Bedin et al., 1987) . Placental sulphatase de®ciency is an X-linked disorder affecting male fetuses and causing ichthyosis. Another disorder that causes very low fetal and maternal estrogen levels is placental P450 aromatase de®ciency. In this case, both the mother and the fetus undergo virilization due to the low levels of androgen aromatization (Shozu et al., 1991) .
Another difference between the mouse and human placenta is the ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 (11b-HSD-2) expression. 11b-HSD-2 inactivates cortisol by transforming it into cortisone. In the human placenta, 11b-HSD-2 activity is thought to protect the fetus from the deleterious effects of maternal glucocorticoids. In mice, 11b-HSD-2 gene expression is switched off in the placenta in mid-gestation (Brown et al., 1996) , and 11b-HSD-2-null mice have normal birth weights. In contrast, in humans, 11b-HSD-2 gene expression increases by a factor of more than 50 during pregnancy and peaks at term (McTernan et al., 2001) . Interestingly, 11b-HSD-2 appears to be regulated by oxygen tension (Alfaidy et al., 2002) . Null mutations of 11b-HSD-2 (Dave-Sharma et al., 1998) and low levels of 11b-HSD-2 gene expression (McTernan et al., 2001) cause intrauterine growth retardation, highlighting the important role of this enzyme in fetal growth.
Human placental hormonal function also includes a gradual increase in the production of human chorionic somatomammotrophic hormone (hCS), also called human placental lactogen (hPL), re¯ecting the development of the syncytiotrophoblast mass. At the end of pregnancy, approximately 1±3 g of hCS is produced each day, yet the physiological role of this molecule is unclear and remains a matter of debate. Human CS may be involved in the adaptation of maternal metabolism to pregnancy and/or might play a direct role in fetal growth, as suggested by the presence of its receptors on cells in some fetal tissues (see Handwerger and Freemark, 2000 for a review). In humans, the syncytiotrophoblast also produces a placental growth hormone (PGH), which differs from pituitary growth hormone by 13 amino acids and possesses one glycosylation site. This hormone has strong somatogenic and weak lactogenic activity. PGH is present in the maternal bloodstream from 12 weeks of amenorrhoea until term, and gradually replaces pituitary growth hormone, which becomes undetectable. PGH is secreted by the placenta in a non-pulsatile manner, and this continuous secretion appears to have important implications for physiological adjustment to gestation, especially in the control of maternal insulin-like growth factor-1 (IGF-1) levels. PGH secretion is regulated both in vitro and in vivo by glucose. Lower maternal levels of PGH are observed in pregnancies with fetal growth retardation. PGH is one example of a trophoblast hormone facilitating maternal metabolic adaptation to pregnancy. In addition, recently acquired data on the production of this hormone in invasive extravillous trophoblasts suggest that the physiological role of PGH might also include a direct effect on placental development by autocrine or paracrine means (for reviews, see Alsat et al., 1997; Lacroix et al., 2002a; .
These strong endocrine activities in the human placenta all occur in the syncytiotrophoblast, the structure which is involved primarily in absorption and exchanges between maternal and fetal blood. In contrast, the structure responsible for maternofetal exchanges in miceÐthe trophoblast layers of the labyrinthÐhas no endocrine function.
In-vitro models for studying human trophoblast development and endocrine functions Particular approaches are required for studies of the human placenta due to the speci®city of its development and endocrine functions, and for evident ethical reasons. In-vitro models have been developed such as organ explants or primary cultures of trophoblast cells. Organ explants can be used to follow trophoblast differentiation over a short period of time. Placental explants from placentas in the ®rst trimester of gestation have been used to A.Malassine Â, J.-L.Frendo and D.Evain-Brion follow the column formation and differentiation of extravillous trophoblasts. Interesting results have been obtained concerning the key role of oxygen tension in modulating human extravillous trophoblast differentiation (Genbacev et al., 1992; Vicovac et al., 1995; Caniggia et al., 2000) . These models are also available for the blocking of expression of a particular gene by means of an antisense strategy (Caniggia et al., 1997) . However, the presence of different cell types precludes ®ne biochemical or molecular biology studies. Extravillous cytotrophoblastic cells were recently isolated from ®rst-trimester anchoring chorionic villi. When plated onto extracellular matrix substrates, these cells reproduce the differentiation process leading to invasion in vivo (Fisher et al., 1989; Burrows et al., 1993; Bischof et al., 1995; Tarrade et al., 2001a) . This extravillous culture model has been used for the identi®cation of factors involved in the modulation of trophoblast invasion. It has also been used for co-culture with decidual cells and, recently, with uterine arteries . Studies of primary cultures have also provided insight into human villous trophoblast differentiation. Isolated villous cytotrophoblasts from early and term placentas adhere to plastic dishes, aggregate and fuse together to form a non-proliferative multinucleated syncytiotrophoblast producing speci®c hormones (Kliman et al., 1986; Alsat et al., 1991; Cronier et al., 1994) . This model can be used for studies of cell±cell fusion, the regulation of hormone production and trophoblast differentiation (Morrish et al., 1998; . It has also been used to explore the genetic control of villous trophoblast development, using subtractive cDNA library (Morrish et al., 1996) and microarray technologies (Aronow et al., 2001; Handwerger and Aronow, 2003) and by proteomic analysis (Hoang et al., 2001) . The comparison of cell culture results with the in-situ data obtained by placental bed biopsies in normal and pathological pregnancies have increased our understanding of placental development at the molecular level (for reviews, see Damsky and Fisher, 1998; Lyall, 2002) . Various permanent trophoblast cell lines are also available (Pattillo and Gey, 1986; Graham et al., 1993) which provide a useful model for studies of certain aspects of gene expression and regulation in cells derived from the trophoblast. However, these highly proliferative cell lines do not necessarily re¯ect the complex phenotype of villous or extravillous trophoblasts (King et al., 2000; Shiverick et al., 2001) . Caution is therefore essential when extrapolating results obtained in these cell lines to normal trophoblasts. Embryonic stem cells now offer an additional basic research tool for investigations of trophoblast development in the mouse (Kunath et al., 2001 ) and in humans (Xu et al., 2002) These cell culture systems have driven progress in identi®cation of the homologues of murine genes expressed during human trophoblast differentiation. However, very few experiments have investigated the regulatory role of these genes and their protein products (Schaiff et al., 2000; Tarrade et al., 2001b; . Meanwhile, the transgenic mouse model has increased our understanding of the genetic basis of the commitment and differentiation of mouse trophoblast subtypes (Kno È¯er et al., 2001; Rossant and Cross, 2001 ). The major ®ndings in this area were recently summarized in several reviews (Kno È¯er et al., 2001; Rossant and Cross, 2001; Cross et al., 2003) .
Another approach to improving our understanding of mouse and human placental development is based on comparative studies of the human and mouse genomes. The human genome has evolved to include some speci®c retroviral sequences (Blond et al., 2001) . These sequences encode proteins involved in the production of proteins speci®c to the human placenta, such as HERV-W envelope protein (syncytin), which has been implicated in syncytiotrophoblast formation (Frendo et al., 2003a) , or in the regulation of genes expressed only in primates or in placenta (Bie Áche et al., 2003) .
In conclusion, due to the unique developmental and endocrine features of the human placenta, investigators must bear in mind the limitations of the experimental models they use. They must be cautious in the interpretation of data emerging from genomic and proteomic strategies, particularly in studies of the pathophysiology of complications of pregnancy with a placental origin, such as preeclampsia and intrauterine growth retardation (Redman and Sargent, 2001 ).
